Hypothesis

Senescent cells release specialized extracellular vesicles (senEVs) that do more than summon antigen‑presenting cells; they also deliver cargo that modulates neutrophil extracellular trap (NET) formation, thereby fine‑tuning the balance between tissue repair and fibrosis. When senescent cell clearance is impaired, persistent senEV signaling drives maladaptive NETosis, converting a protective negotiation into a pro‑fibrotic cascade.

Mechanistic rationale

• SenEVs described in [5] contain six unique ligands that recruit APCs and activate CD4⁺ T cells. Proteomic profiling of senEVs from hepatic stellate cells reveals enrichment of myeloperoxidase‑activating peptides and citrullinated histones, known NET‑inducing motifs.
• NETs extrude DNA‑histone scaffolds that trap pathogens but also serve as a scaffold for collagen deposition; excessive NETosis correlates with liver fibrosis in models of cholestatic injury.
• In liver injury, senescent hepatic stellate cells (HSCs) recruit immune cells that limit fibrosis ([3]). We propose that a fraction of this recruitment is mediated via senEV‑driven NETosis, which creates a transient, localized inflammatory milieu that activates stellate cell apoptosis via DNase‑I–sensitive pathways.
• When macrophage‑dependent clearance of senescent cells fails (as in aging or chronic injury), senEV accumulation sustains NETosis, leading to persistent extracellular DNA that activates TLR9 on HSCs, promoting a profibrotic phenotype ([6],[7]).

Testable predictions

1. In vivo – Mice with hepatocyte‑specific p16‑3MR senescent cell ablation will show reduced hepatic senEV levels, decreased citrullinated histone H3 (a NET marker), and attenuated collagen deposition after CCl₄ injury compared with controls.
2. In vitro – Isolated senEVs from senescent HSCs will induce NET formation in neutrophils isolated from wild‑type mice; pretreatment with NET‑inhibitory DNase I or PAD4 inhibitor will block senEV‑stimulated collagen‑I expression in HSC cultures.
3. Biomarker – Serum levels of senEV‑associated miR‑122‑5p (predicted to target PAD4) will inversely correlate with NET biomarkers and fibrosis stage in human NAFLD patients; longitudinal sampling after senolytic treatment will reveal a rise in miR‑122‑5p concurrent with falling NET scores.
4. Rescue – Administering PAD4 inhibitor GSK484 to aged mice with accumulated senescent HSCs will normalize NETosis, reduce TLR9‑driven TGF‑β1 signaling, and improve liver histology without altering senescent cell numbers.

Experimental approach

• Generate a triple‑reporter mouse: p16‑3MR (senescent cell ablation), LysM‑Cre‑Rosa26‑tdTomato (macrophage tracking), and MPO‑GFP (NET visualization). Induce liver injury, treat with or without ganciclovir, and quantify senEV uptake by neutrophils using flow cytometry for CD63‑positive vesicles.
• Perform mass spectrometry on senEVs isolated from p16⁺ HSCs to identify NET‑related cargo; validate hits with western blot for citrullinated histone H3 and MPO.
• Use transgenic PAD4‑fl/fl mice crossed to LysM‑Cre to specifically delete PAD4 in neutrophils; assess fibrosis outcomes after injury.
• In human cohorts, isolate senEVs from plasma via size‑exclusion chromatography, quantify miR‑122‑5p by qPCR, and correlate with serum cfDNA‑MPO complexes and ELF fibrosis scores.

If senEV‑driven NETosis proves to be a pivotal switch that converts senescent cell‑mediated repair into fibrosis, targeting this axis—either by boosting senEV clearance, inhibiting PAD4, or supplementing protective miRNAs—could uncouple the beneficial “hostage negotiator” role of senescence from its deleterious chronic manifestation.